SAMSUNG BIOLOG
Weitere Aktien aus dem Sektor Gesundheit
Über SAMSUNG BIOLOGICS CO.,LTD.
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in the production of antibody drugs. The Company operates through two segments. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides biopharmaceutical contract manufacturing and cell line development services. The Biopharmaceutical Development and Commercialization segment primarily engages in the development and commercialization of biosimilars.
Q1 2026 Samsung Biologics Co Ltd Earnings Release
21.04.2026
10:59
Veröffentlichungen von Geschäftszahlen
Q2 2026 Samsung Biologics Co Ltd Earnings Release
21.07.2026
10:59
Veröffentlichungen von Geschäftszahlen